MRMI of EDB-FN with a significantly reduced dose of MT218 can facilitate effective non-invasive assessment and therapeutic monitoring of drug-resistant CRC, highlighting the translational potential of MT218-mediated EDB-FN-targeting MRMI in active surveillance and monitoring of drug-resistant neoplasms. Here, FN1 is linked to neoplasm.